TABLE 2.
Factors associated with seroconversion to booster in those without seroconversion to initial vaccine series
| Variable | All patients with no seroconversion before booster | No postbooster seroconversion | Positive postbooster seroconversion | ||||
|---|---|---|---|---|---|---|---|
| No. | Column % | No. | Row % | No. | Row % | p | |
| No. | 85 | 37 | 48 | ||||
| Age: Median (IQR), years | 73.4 (65.9–78.9) | 75.3 (65.5–79.0) | 72.9 (67.9–78.3) | .91 | |||
| Sex | .270 | ||||||
| Women | 50 | 58.8 | 19 | 38.0 | 31 | 62.0 | |
| Men | 35 | 41.2 | 18 | 51.4 | 17 | 48.6 | |
| Histology | < .001 | ||||||
| Indolent B‐cell | 19 | 22.4 | 3 | 15.8 | 16 | 84.2 | |
| Aggressive B‐cell | 35 | 41.2 | 25 | 71.4 | 10 | 28.6 | |
| Other lymphoma | 3 | 3.5 | 0 | 0.0 | 3 | 100.0 | |
| Myeloid | 5 | 5.9 | 2 | 40.0 | 3 | 60.0 | |
| CLL | 12 | 14.1 | 6 | 50.0 | 6 | 50.0 | |
| Myeloma/MGUS | 11 | 12.9 | 1 | 9.1 | 10 | 90.9 | |
| Disease status at the time of booster | .82 | ||||||
| Off treatment | 55 | 64.7 | 23 | 41.8 | 32 | 58.2 | |
| On treatment | 30 | 35.3 | 14 | 46.7 | 16 | 53.3 | |
| Anti–B‐cell antibody | .03 | ||||||
| No | 25 | 29.4 | 6 | 24.0 | 19 | 76.0 | |
| Yes | 60 | 70.6 | 31 | 51.7 | 29 | 48.3 | |
| Stem cell transplantation | .13 | ||||||
| No | 77 | 90.6 | 36 | 46.8 | 41 | 53.2 | |
| Yes | 8 | 9.4 | 1 | 12.5 | 7 | 87.5 | |
| WBC: Median (IQR), ×109/L | 5.3 | (3.85–6.35) | 5.1 | (3.8–6.4) | 5.4 | (3.9–6.3) | .77 |
| ALC: Median (IQR), ×109/L | 1.0 | (0.7–1.4) | 0.9 | (0.4–1.2) | 1.1 | (0.8–1.5) | .044 |
| COVID booster vaccine | .39 | ||||||
| BNT162b2/Pfizer | 52 | 61.2 | 20 | 38.5 | 32 | 61.5 | |
| mRNA‐1273/Moderna | 28 | 32.9 | 15 | 53.6 | 13 | 46.4 | |
| Ad26.COV2.S/J&J | 5 | 5.9 | 2 | 40.0 | 3 | 60.0 | |
Abbreviations: Ad26.COV2.S, adenovirus serotype 26 against the severe acute respiratory‐coronavirus 2 spike protein; CLL, chronic lymphocytic leukemia; COVID, coronavirus disease; IQR, interquartile range; MGUS, monoclonal gammopathy of undetermined significance; mRNA, messenger RNA; WW, watchful waiting.